ArticleAmerican journal of cancer research2025
Clinical impact and safety of continuous renal replacement therapy in critically ill patients with solid tumors and acute kidney injury: a retrospective cohort analysis.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the efficacy and safety of continuous renal replacement therapy (CRRT) in critically ill patients with solid tumors complicated by acute kidney injury (AKI) in the intensive care unit (ICU).
methodsIn this retrospective cohort study, 580 ICU patients with solid tumors and AKI were enrolled and stratified into a CRRT group (n = 300) and a non-CRRT group (n = 280). CRRT was initiated within 12 hours of ICU admission in patients meeting Kidney Disease Improving Global Outcomes stage 3 criteria. Propensity score matching (PSM) was performed to balance baseline characteristics. Primary outcomes included AKI remission, metabolic stabilization, and 90-day survival. Multivariable logistic regression and XGBoost machine learning were used to identify prognostic factors and build predictive models.
resultsAfter PSM, baseline characteristics were well balanced. CRRT significantly improved renal and metabolic parameters within 72 hours, including reductions in serum creatinine, blood urea nitrogen, and lactate (all P < 0.001), with a trend toward increased urine output. The CRRT group had higher AKI remission (64.54% vs. 49.65%, P < 0.001) and 90-day survival rates (47.52% vs. 39.01%, P = 0.012), albeit with greater dialysis dependence (19.15% vs. 0.00%, P < 0.001). Adverse events were comparable. XGBoost models achieved AUCs of 0.78 and 0.75 for mortality and AKI remission, respectively.
conclusionsCRRT improves renal recovery, metabolic status, and survival in critically ill cancer patients with AKI, with an acceptable safety profile. Machine learning offers promising tools for individualized outcome prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.